Novo Nordisk Sues Eli Lilly Over Allegedly Misleading GLP-1 Ad Campaigns

What Happened

Novo Nordisk has taken its marketing war with Eli Lilly into federal court, filing a lawsuit that accuses its rival of running "multiple misleading national ad campaigns" for the GLP-1 drugs Zepbound and Mounjaro. The suit, filed in the U.S. District Court for New Jersey, seeks a permanent injunction forcing Lilly to pull its comparative advertising across all platforms and to run a corrective advertising campaign.

Novo says it first sent a formal cease-and-desist request asking Lilly to pull down or meaningfully correct the ads, and filed suit only after that request was refused. The company has also threatened to seek a preliminary injunction to immediately block the ads if they are not withdrawn voluntarily in the coming days.

Who Is Affected

The campaigns at the center of the dispute include a head-to-head Zepbound-versus-Wegovy spot citing average weight loss of 50 pounds for Zepbound users versus 33 pounds for Wegovy users — an ad Novo says aired during widely viewed global sporting broadcasts as well as on TikTok and Facebook. Novo argues the comparison creates "widespread confusion" because it omits critical context: a higher dose of Wegovy approved by the FDA in March showed average weight loss of roughly 47 pounds in clinical testing.

A similar Mounjaro-versus-Ozempic campaign compares the two drugs at an older dose of Ozempic, ignoring a more effective maintenance dose the FDA approved more than four years ago, according to the complaint. Patients actively comparing GLP-1 options are the practical audience for these claims, and the case is ultimately about what they were told.

Timeline

• March 2026 — FDA approves a higher-dose Wegovy formulation, which Novo says is excluded from Lilly's comparisons
• July 2026 — Novo sends a formal cease-and-desist request; Lilly declines to change the ads
• July 2026 — Novo files suit in the U.S. District Court for New Jersey
• Ongoing — the case remains pending, with a preliminary injunction threatened if the ads stay up

What This Means for Researchers

The litigation spotlights a structural issue in GLP-1 marketing: head-to-head results depend heavily on which doses are compared. Novo alleges Lilly "intentionally selected outdated studies that compare Lilly's highest doses against lower doses of Novo Nordisk's medicines, deceptively presenting those results as proof of broad, product-level superiority." Lilly counters that its advertising is truthful, transparent, and grounded in the most direct scientific evidence available — the only head-to-head studies that have been conducted.

For anyone evaluating GLP-1 data, the case is a reminder that a comparative claim can be technically accurate and still contested. The commercial stakes are sharp: Novo's once-dominant position has eroded to roughly 40 percent of the GLP-1 market, with Lilly holding about 60 percent.

How to Verify Your Peptides

Brand-name GLP-1s are among the most counterfeited medicines in the world, so verification matters whether a vial is branded or compounded: check certificates of analysis, use third-party lab testing, review HPLC versus LC-MS methods, and understand identity, purity, and fill weight testing.

Safe Alternatives

For legitimate sourcing, see our semaglutide profile, our tirzepatide profile, and our vetted vendor directory. Our semaglutide dosage calculator helps researchers plan reconstitution accurately.

Sources

Industry reports; federal court filings; regulatory announcements.